<DOC>
	<DOCNO>NCT01307059</DOCNO>
	<brief_summary>This Swedish , Multicentre , Observational Registry study Adherence Long Term Outcomes Therapy paediatric subject use Easypod™ electromechanical device growth hormone treatment assess level adherence subject receive SAIZEN® via Easypod™ .</brief_summary>
	<brief_title>To Assess Level Adherence Subjects Receiving SAIZEN® Via Easypod™ Sweden</brief_title>
	<detailed_description>Subjects enrol multicenter longitudinal observational registry . Parents/subjects provide Informed Consent/assent upload data population-based analysis optionally adhere patient adherence support program design improve adherence , ultimately , clinical outcome . Adherence data primarily derive Easypod™ device combine physician data entry outcome measure . Data collect retrospectively prospectively . This allow establishment adherence profile explore hypothesis patient adherence support program improve adherence subsequent clinical outcome . Collected data also analyze multinational pooled analysis comparable national study . Primary Objective : • To assess level adherence subject receive SAIZEN® via Easypod™ Secondary Objectives : - To describe impact adherence clinical outcome subject receive SAIZEN® via Easypod™ - To identify adherence subject profiling base age , gender , self injection , time treatment , medical history time enrollment - To assess impact adherence Insulin-like Growth Factor 1 ( IGF1 ) ( i.e . , within normal range ) Other Objectives : • To assess impact adherence average blood glucose ( HbA1C )</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Administered growth hormone via EasypodTM electromechanical device accord Summary Product Characteristics ( SmPC ) Over age &gt; 2 year old Under &lt; 18 year age , 18 year age without fusion growth plat Parent 's guardian 's write informed consent , give enter data registry , understand subject parent/guardian may withdraw consent time without prejudice future medical care . If child old enough read write , separate assent form give defined appropriate jurisdiction country . Subjects take growth hormone growth plate fuse ( i.e . take growth hormone 's metabolic effect ) Contraindications SAIZEN® define SmPC Use investigational drug participation interventional clinical study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Growth disorder</keyword>
	<keyword>Saizen</keyword>
	<keyword>Easypod</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>Pediatric subject</keyword>
</DOC>